Nitrogen-containing heterocyclic compounds, their preparation methods and their pharmaceutical applications
By developing nitrogen-containing heterocyclic compounds that are selective for PARP1, the problems of low selectivity and high toxicity of existing PARP inhibitors in cancer treatment have been solved, and effective killing of tumor cells with homologous recombination defects has been achieved.
Patent Information
- Application Number
- CN202280027629.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-02
- Filing Date
- 2022-05-24
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-05-24
AI Technical Summary
Existing PARP inhibitors suffer from low selectivity and high toxicity when treating cancer, especially in non-BRCA-mutated tumors, where they are difficult to effectively kill tumor cells with homologous recombination defects.
A nitrogen-containing heterocyclic compound of general formula (IM) or a pharmaceutically acceptable salt thereof has been developed, which has a strong selective inhibitory effect on PARP1 and selectively kills tumor cells with HRD by causing DNA double-strand breaks due to the collapse of the replication fork in the S phase.
It provides a selective inhibitor of PARP1, which improves the efficacy of cancer treatment and reduces toxicity, especially showing significant killing effects in non-BRCA-mutated tumors.
Smart Images

Figure CN117177971B_ABST
Abstract
Description
Technical Field
[0001] This disclosure pertains to the pharmaceutical field and relates to a nitrogen-containing heterocyclic compound, its preparation method, and its pharmaceutical application. In particular, this disclosure relates to nitrogen-containing heterocyclic compounds of general formula (IM), their preparation methods, pharmaceutical compositions containing such compounds, and their use as PARP1 inhibitors and in the preparation of medicaments for the treatment and / or prevention of cancer. Background Technology
[0002] Poly(ADP-ribose) polymerase 1 (PARP1), first reported over 50 years ago, has since been found to play crucial roles in DNA repair, maintaining genome integrity, and regulating various metabolic and signal transduction processes. PARP1 catalyzes the transfer of ADP-ribose residues from NAD+ to target substrates, constructing a poly(ADP-ribose) (PAR) chain. The formation and clearance of PAR chains occur in almost all eukaryotic cells.
[0003] ADP-ribosylation is a post-translational modification of proteins widely present in various physiological and pathological processes. It refers to the binding of one or more ADP-ribose units to a specific site on a protein under the catalysis of an enzyme. PARP1 is the first member of the PARP superfamily, which consists of proteins homologous to PARP1 and currently has 17 members, four of which (PARP1, PARP2, PARP5A, and PARP5B) can synthesize PAR chains. Most other enzymes in the family can only construct a single ADP-ribose unit and are therefore classified as mono(ADP-ribosyl)ases (MARs).
[0004] PARP1 and PARP2 have been extensively studied for their roles in DNA damage repair. PARP1 is activated by DNA damage and catalyzes the movement of the poly(ADP-ribosyl) (PAR) chain toward target proteins. This post-translational modification, called poly-ADP-ribosylation (PARylation), mediates the recruitment of other DNA repair factors to the DNA damage site. After completing this recruitment, PARP auto-PARylation triggers the release of bound PARP from the DNA, allowing access to other DNA repair proteins to complete the repair. Therefore, PARP binding to the damaged site, its catalytic activity, and its eventual release from the DNA are all crucial steps in how cancer cells respond to DNA damage induced by chemotherapy and radiotherapy.
[0005] Inhibiting PARP family enzymes has been used as a strategy to selectively kill cancer cells by inactivating complementary DNA repair pathways. Numerous preclinical and clinical studies have shown that tumor cells with harmful alterations in the key tumor suppressor proteins BRCA1 or BRCA2, which are involved in double-strand DNA break (DSB) repair via harmful recombination (HR), are selectively sensitive to small molecules such as inhibitors of the PARP family of DNA repair enzymes. These tumors have insufficient homologous recombination repair (HRR) pathways and rely on the survival function of PARP enzymes. Although PARP inhibitor therapy primarily targets BRCA-mutated cancers, PARP inhibitors have been clinically tested in non-BRCA-mutated tumors that exhibit homologous recombination deficiency (HRD).
[0006] Compared to other PARP1 / 2 inhibitors, PARP inhibitors with enhanced selectivity for PARP1 can exhibit improved efficacy and reduced toxicity. We believe that strong selective inhibition of PARP1 will lead to PARP1 capture on DNA, resulting in DNA double-strand breaks (DSBs) through the collapse of the replication fork in S phase. PARP1-DNA capture is an effective mechanism for selectively killing tumor cells with HRD.
[0007] Therefore, there is an urgent clinical need for effective and safe PARP inhibitors, especially PARP inhibitors that are selective for PARP1.
[0008] The relevant patent applications that have been published are WO2021013735A1, WO2021260092A1, WO2009053373A1, WO2008107478A1, etc. Summary of the Invention
[0009] The purpose of this disclosure is to provide a compound of general formula (IM) or a pharmaceutically acceptable salt thereof:
[0010]
[0011] in:
[0012] X and Y may be the same or different, and each is independently selected from (CR). 4a R 4b ) m NR 5 (CR 4c R 4d ) r C(O)NR 5 NR 5 C(O), C(O) and O(CR) 4e R 4f ) n ;
[0013] R 4a R 4b R 4c R 4d R 4e and R 4f They may be the same or different, and each is independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups;
[0014] R 5 Selected from hydrogen atoms, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups;
[0015] G 1 G 2 and G 3 Whether the same or different, and each independently constitutes a CR 6 Or nitrogen atoms;
[0016] R 0 R 1 and R 6 They may be the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8 cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0017] Each R 2 They may be the same or different, and each is independently selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, oxo, cyano, -NR 7a R 7b hydroxyl and hydroxyalkyl;
[0018] Each R 3 They may be the same or different, and each is independently selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR8 -C(O)NR 7a R 7b -S(O) p R 8 cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0019] R 7a R 7b R 9a and R 9b They may be the same or different, and each is independently selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;
[0020] Or R 7a and R 7b Together with the attached nitrogen atom, it forms a heterocyclic group, R 9a and R 9b Together with the attached nitrogen atom, a heterocyclic group is formed, wherein the heterocyclic group is optionally substituted by one or more substituents selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0021] R 8 The group is selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;
[0022] p is 0, 1, or 2;
[0023] m can be 0, 1, 2, 3, or 4;
[0024] n can be 0, 1, 2, 3, or 4;
[0025] r can be 0, 1, 2, 3, or 4;
[0026] s is 0, 1, 2, 3, or 4; and
[0027] t can be 0, 1, 2 or 3.
[0028] In some embodiments of this disclosure, the compound represented by general formula (IM) or a pharmaceutically acceptable salt thereof is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:
[0029]
[0030] in:
[0031] X and Y may be the same or different, and each is independently selected from (CR). 4a R 4b ) m NR 5 (CR 4c R 4d ) r C(O)NR 5 NR 5 C(O), C(O) and O(CR) 4e R 4f ) n ;
[0032] R 4a R 4b R 4c R 4d R 4e and R 4f They may be the same or different, and each is independently selected from hydrogen atoms, halogens, alkyl groups, haloalkyl groups, hydroxyalkyl groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups;
[0033] R 5 Selected from hydrogen atoms, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups;
[0034] G 1 G 2 and G 3 Whether the same or different, and each independently constitutes a CR 6 Or nitrogen atoms;
[0035] R 1 and R 6 They may be the same or different, and each is independently selected from hydrogen atom, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0036] Each R 2 They may be the same or different, and each is independently selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, oxo, cyano, -NR 7a R 7b hydroxyl and hydroxyalkyl;
[0037] Each R 3 They may be the same or different, and each is independently selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 -C(O)NR 7a R 7b -S(O) p R 8 cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each independently and optionally selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, -NR 9a R 9b The substance is substituted by one or more substituents selected from hydroxyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl;
[0038] R 7a R 7b R 9a and R 9b They may be the same or different, and each is independently selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;
[0039] Or R 7a and R 7b Together with the attached nitrogen atom, it forms a heterocyclic group, R 9a and R 9bTogether with the attached nitrogen atom, a heterocyclic group is formed, wherein the heterocyclic group is optionally substituted by one or more substituents selected from halogen, oxo, alkyl, alkoxy, haloalkyl, haloalkoxy, cyano, amino, nitro, hydroxy, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0040] R 8 The group is selected from hydrogen atoms, alkyl, hydroxyalkyl, cycloalkyl and heterocyclic groups, wherein each of the alkyl, cycloalkyl and heterocyclic groups is independently and optionally substituted by one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl and haloalkoxy;
[0041] p is 0, 1, or 2;
[0042] m can be 0, 1, 2, 3, or 4;
[0043] n can be 0, 1, 2, 3, or 4;
[0044] r can be 0, 1, 2, 3, or 4;
[0045] s is 0, 1, 2, 3, or 4; and
[0046] t can be 0, 1, 2 or 3.
[0047] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), or pharmaceutically acceptable salts thereof, wherein X is (CR 4a R 4b ) m Or C(O); where R 4a R 4b And m is as defined in general formula (IM); preferably, X is selected from CH2, CH2CH2 and C(O).
[0048] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), or pharmaceutically acceptable salts thereof, wherein Y is O(CR) 4e R 4f ) n or NR 5 (CR 4c R 4d ) r ;where R 4c R 4d R 4e R 4f R 5 , n and r are as defined in general formula (IM); preferably, Y is selected from O, OCH2, NH and NCH3.
[0049] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), or pharmaceutically acceptable salts thereof, wherein X is (CR4a R 4b ) m Or C(O), Y is O(CR) 4e R 4f ) n or NR 5 (CR 4c R 4d ) r Preferably, X is (CR) 4a R 4b ) m And Y is O(CR) 4e R 4f ) n , or X is (CR 4a R 4b ) m And Y is NR 5 (CR 4c R 4d ) r Or X is C(O) and Y is NR. 5 (CR 4c R 4d ) r ;where R 4a R 4b R 4c R 4d R 4e R 4f R 5 , m, n and r are as defined in general formula (IM); more preferably, XY are selected from CH2O, CH2OCH2, CH2CH2O, C(O)NH, CH2NH and CH2NCH3.
[0050] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), or pharmaceutically acceptable salts thereof, wherein R 4c and R 4d They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 4c and R 4d All are hydrogen atoms.
[0051] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), or pharmaceutically acceptable salts thereof, wherein R 4e and R 4f They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 4e and R 4f All are hydrogen atoms.
[0052] In some embodiments of this disclosure, the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof, wherein R 0 Selected from hydrogen atoms, halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 0 It is a hydrogen atom or a halogen; more preferably, R 0 It is a hydrogen atom or F; most preferably, R 0 It is a hydrogen atom.
[0053] In some embodiments of this disclosure, the compounds represented by general formula (IM) or general formula (I), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (II-1) or pharmaceutically acceptable salts thereof:
[0054]
[0055] in:
[0056] X is (CR) 4a R 4b ) m ;
[0057] G 1 To G 3 R 1 To R 3 R 4a R 4b , s, t, m and n are as defined in the general formula (IM).
[0058] In some embodiments of this disclosure, the compounds represented by general formula (IM) or general formula (I), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (II-2) or pharmaceutically acceptable salts thereof:
[0059]
[0060] in:
[0061] X is (CR) 4a R 4b ) m Or C(O);
[0062] G 1 To G 3 R 1 To R 3 R 4a R 4b R 5 , s, t, m and r are as defined in the general formula (IM).
[0063] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2), or their pharmaceutically acceptable salts, wherein each R 2 They may be the same or different, and each is independently selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl and C 1-6 Halogenated alkoxy groups.
[0064] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2) or their pharmaceutically acceptable salts are used, wherein s is 0.
[0065] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2), or their pharmaceutically acceptable salts, wherein G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 Or G 1 and G 2 Both are CH, and G 3 For nitrogen atoms; or G 1 For nitrogen atoms, G 2 It is CH, and G 3 For CR 6 Preferably, G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 ;where R 6 As defined in the general formula (IM).
[0066] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2), or their pharmaceutically acceptable salts, wherein G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 Or G 1 and G 2 Both are CH, and G 3 For nitrogen atoms; or G 1 For nitrogen atoms, G 2 It is CH, and G 3 For CR 6 ;where R 6 As defined in general formula (IM); preferably, G 1 For CH, G 2 It is a nitrogen atom, and G3 For CR 6 Or G 1 For nitrogen atoms, G 2 It is CH, and G 3 For CR 6 ;where R 6 As defined in the general formula (IM).
[0067] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2) or their pharmaceutically usable salts are used, wherein t is 1 or 2; preferably, t is 1.
[0068] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2), or their pharmaceutically acceptable salts, wherein R 3 Selected from halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 1-6 Hydroxyalkyl, cyano, -NR 7a R 7b hydroxyl group, -C(O)R 8 -C(O)OR 8 and -C(O)NR 7a R 7b Preferably, R 3 -C(O)NR 7a R 7b ;where R 7a R 7b and R 8 As defined in general formula (IM); more preferably, R 3 It is -C(O)NHCH3.
[0069] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2) or their pharmaceutically acceptable salts are used, wherein m is 1 or 2.
[0070] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (II-2), or their pharmaceutically acceptable salts, wherein R 4a and R 4b They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 Alkyl and C 1-6 Halogenated alkyl; preferably, R 4a and R 4b All are hydrogen atoms.
[0071] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), and (II-2) or their pharmaceutically usable salts are used, wherein r is 0 or 1; preferably, r is 0.
[0072] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), and general formula (II-1), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (III-1) or pharmaceutically acceptable salts thereof:
[0073]
[0074] in:
[0075] m1 is 0 or 1;
[0076] R 1 R 6 R 7a R 7b And n is as defined in the general formula (IM).
[0077] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), and (III-1), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (III-1-A) or pharmaceutically acceptable salts thereof.
[0078]
[0079] in:
[0080] m1 is 0 or 1;
[0081] R 1 R 6 R 7a R 7b And n is as defined in the general formula (IM).
[0082] In some embodiments of this disclosure, the compounds represented by general formula (IM), general formula (I), and general formula (II-2), or pharmaceutically acceptable salts thereof, are compounds represented by general formula (III-2) or pharmaceutically acceptable salts thereof:
[0083]
[0084] in:
[0085] X is CH2 or C(O);
[0086] R 1 R 5 R 6 R 7a and R 7bAs defined in the general formula (IM).
[0087] In some embodiments of this disclosure, the compounds or pharmaceutically acceptable salts of the general formulas (IM), (I), (II-1), (II-2), (III-1), (III-1-A), and (III-2) are used, wherein R 1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; preferably, R 1 C 1-6 Alkyl; more preferably, R 1 It is an ethyl group.
[0088] In some embodiments of this disclosure, the compounds or pharmaceutically acceptable salts of the general formulas (IM), (I), (II-1), (II-2), (III-1), (III-1-A), and (III-2) are used, wherein R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; preferably, R 6 It is a hydrogen atom.
[0089] In some embodiments of this disclosure, the compounds or pharmaceutically acceptable salts of the general formulas (IM), (I), (II-1), (II-2), (III-1), (III-1-A), and (III-2) are used, wherein R 7a and R 7b Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 Alkyl, C 1-6 Hydroxyalkyl, 3- to 8-membered cycloalkyl and 3- to 8-membered heterocyclic groups; preferably, R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; more preferably, R 7a For hydrogen atoms, R 7b It is a methyl group.
[0090] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-1), (III-1), and (III-1-A), or their pharmaceutically acceptable salts, are used, wherein n is 0 or 1.
[0091] In some embodiments of this disclosure, the compounds represented by general formulas (IM), (I), (II-2), and (III-2), or pharmaceutically acceptable salts thereof, wherein R 5 It is a hydrogen atom or a carbon atom. 1-6 Alkyl; preferably, R 5 It can be a hydrogen atom or a methyl group.
[0092] In some embodiments of this disclosure, the compound represented by the general formula (IM) or a pharmaceutically acceptable salt thereof, wherein X is (CR 4a R 4b ) m Or C(O), Y is O(CR) 4e R 4f ) n or NR 5 (CR 4c R 4d ) r G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 Or G 1 For nitrogen atoms, G 2 It is CH, and G 3 For CR 6 ;R 0 It is a hydrogen atom or a halogen; R 1 C 1-6 Alkyl; R 3 -C(O)NR 7a R 7b ;R 4a R 4b R 4c R 4d R 4e and R 4f All are hydrogen atoms; R 5 It is a hydrogen atom or a carbon atom. 1-6 Alkyl; R 6 For hydrogen atoms; R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; m is 1 or 2; n is 0 or 1; r is 0 or 1; s is 0; t is 1.
[0093] In some embodiments of this disclosure, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein X is (CR 4a R 4b ) m Or C(O), Y is O(CR) 4e R 4f) n or NR 5 (CR 4c R 4d ) r G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 Or G 1 and G 2 It is CH, and G 3 For nitrogen atoms; or G 1 For nitrogen atoms, G 2 It is CH, and G 3 For CR 6 ;R 1 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; R 3 -C(O)NR 7a R 7b ;R 4a R 4b R 4c R 4d R 4e and R 4f All are hydrogen atoms; R 5 It is a hydrogen atom or a carbon atom. 1-6 Alkyl; R 6 Selected from hydrogen atoms, halogens, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups and C 1-6 Hydroxyalkyl; R 7a and R 7b Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 Alkyl, C 1-6 Hydroxyalkyl, 3- to 8-membered cycloalkyl and 3- to 8-membered heterocyclic groups; m is 1 or 2; n is 0 or 1; r is 0 or 1; s is 0; t is 1 or 2.
[0094] In some embodiments of this disclosure, the compound represented by general formula (II-1) or a pharmaceutically acceptable salt thereof, wherein X is (CR 4a R 4b ) m G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 ;R 1C 1-6 Alkyl; R 3 -C(O)NR 7a R 7b ;R 4a and R 4b All are hydrogen atoms; R 6 For hydrogen atoms; R 7a and R 7b Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 Alkyl, C 1-6 Hydroxyalkyl, 3- to 8-membered cycloalkyl and 3- to 8-membered heterocyclic groups; s is 0; t is 1; m is 1 or 2; n is 0 or 1.
[0095] In some embodiments of this disclosure, the compound represented by general formula (II-2) or a pharmaceutically acceptable salt thereof, wherein X is (CR 4a R 4b ) m Or C(O); G 1 For CH, G 2 It is a nitrogen atom, and G 3 For CR 6 ;R 1 C 1-6 Alkyl; R 3 -C(O)NR 7a R 7b ;R 4a and R 4b All are hydrogen atoms; R 5 It is a hydrogen atom or a carbon atom. 1-6 Alkyl; R 6 For hydrogen atoms; R 7a and R 7b Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 Alkyl, C 1-6 Hydroxyalkyl, 3- to 8-membered cycloalkyl and 3- to 8-membered heterocyclic groups; s is 0; t is 1; m is 1 or 2; r is 0.
[0096] In some embodiments of this disclosure, the compound represented by general formula (III-1) or general formula (III-1-A) or a pharmaceutically acceptable salt thereof, wherein R 1 C 1-6 Alkyl; R 6 For hydrogen atoms; R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 Alkyl; m1 is 0 or 1; n is 0 or 1.
[0097] In some embodiments of this disclosure, the compound represented by general formula (III-2) or a pharmaceutically acceptable salt thereof, wherein X is CH2 or C(O); R1 C 1-6 Alkyl; R 5 It is a hydrogen atom or a carbon atom. 1-6 Alkyl; R 6 For hydrogen atoms; R 7a and R 7b They may be the same or different, and each is independently a hydrogen atom or a carbon atom. 1-6 alkyl.
[0098] Table A lists typical compounds disclosed herein, including but not limited to:
[0099]
[0100]
[0101]
[0102]
[0103] Another aspect of this disclosure relates to compounds of the general formula (IMa) or salts thereof:
[0104]
[0105] in:
[0106] t is 1, 2, or 3;
[0107] X, Y, R 2 R 3 And s are as defined by the general formula (IM) compound.
[0108] Another aspect of this disclosure relates to compounds of general formula (II-1a) or salts thereof:
[0109]
[0110] in:
[0111] X, R 2 R 3 , s, t and n are as defined for compounds of general formula (II-1).
[0112] Another aspect of this disclosure relates to compounds of general formula (II-2a) or salts thereof:
[0113]
[0114] in:
[0115] X, R 2 R 3 R 5, s, t, and r are as defined for compounds of general formula (II-2). Another aspect of this disclosure relates to compounds of general formula (III-1a) or salts thereof:
[0116]
[0117] in:
[0118] m1 is 0 or 1;
[0119] R 7a R 7b And n is as defined by compounds of general formula (III-1).
[0120] Another aspect of this disclosure relates to compounds of the general formula (III-1-Aa) or salts thereof:
[0121]
[0122] in:
[0123] m1 is 0 or 1;
[0124] R 7a R 7b And n is as defined by the general formula (III-1-A) compounds.
[0125] Another aspect of this disclosure relates to compounds of general formula (III-2a) or salts thereof:
[0126]
[0127] in:
[0128] X, R 5 R 7a and R 7b As defined in general formula (III-2).
[0129] Table B lists typical intermediate compounds disclosed herein, including but not limited to:
[0130]
[0131]
[0132]
[0133]
[0134] Another aspect of this disclosure relates to a method for preparing a compound of general formula (IM) or a pharmaceutically acceptable salt thereof, the method comprising:
[0135]
[0136] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IMb) to give a compound of general formula (IM) or a pharmaceutically usable salt thereof.
[0137] in:
[0138] L is a halogen, preferably a chlorine atom;
[0139] X, Y, G 1 To G 3 R 0 To R 3 , s and t are as defined in the general formula (IM).
[0140] Another aspect of this disclosure relates to a method for preparing a compound of general formula (I) or a pharmaceutically acceptable salt thereof, the method comprising:
[0141]
[0142] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) to give a compound of general formula (I) or a pharmaceutically usable salt thereof;
[0143] in:
[0144] L is a halogen, preferably a chlorine atom;
[0145] X, Y, G 1 To G 3 R 1 To R 3 , s and t are as defined in general formula (I).
[0146] Another aspect of this disclosure relates to a method for preparing a compound of general formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising:
[0147]
[0148] A compound of general formula (II-1a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) to give a compound of general formula (II-1) or a pharmaceutically usable salt thereof;
[0149] in:
[0150] L is a halogen, preferably a chlorine atom;
[0151] X, G 1 To G 3 R 1 To R 3 , s, t and n are as defined in general formula (II-1).
[0152] Another aspect of this disclosure relates to a method for preparing a compound of general formula (II-2) or a pharmaceutically acceptable salt thereof, the method comprising:
[0153]
[0154] A compound of general formula (II-2a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) to give a compound of general formula (II-2) or a pharmaceutically usable salt thereof;
[0155] in:
[0156] L is a halogen, preferably a chlorine atom;
[0157] X, G 1 To G 3 R 1 To R 3 R 5 , s, t and r are as defined in general formula (II-2).
[0158] Another aspect of this disclosure relates to a method for preparing a compound of general formula (III-1) or a pharmaceutically acceptable salt thereof, the method comprising:
[0159]
[0160] A compound of general formula (III-1a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (VI) to give a compound of general formula (III-1) or a pharmaceutically usable salt thereof.
[0161] in:
[0162] m1 is 0 or 1;
[0163] L is a halogen, preferably a chlorine atom;
[0164] R 1 R 6 R 7a R 7b And n is as defined in general formula (III-1).
[0165] Another aspect of this disclosure relates to a method for preparing a compound of general formula (III-1-A) or a pharmaceutically acceptable salt thereof, the method comprising:
[0166]
[0167] A compound of general formula (III-1-Aa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (VI) to give a compound of general formula (III-1-A) or a pharmaceutically usable salt thereof.
[0168] in:
[0169] m1 is 0 or 1;
[0170] L is a halogen, preferably a chlorine atom;
[0171] R 1 R 6 R 7a R 7b And n is as defined in general formula (III-1-A).
[0172] Another aspect of this disclosure relates to a method for preparing a compound of general formula (III-2) or a pharmaceutically acceptable salt thereof, the method comprising:
[0173]
[0174] A compound of general formula (III-2a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (VI) to give a compound of general formula (III-2) or a pharmaceutically usable salt thereof.
[0175] in:
[0176] L is a halogen, preferably a chlorine atom;
[0177] X, R 1 R 5 R 6 R 7a and R 7b As defined in general formula (III-2).
[0178] Another aspect of this disclosure relates to a pharmaceutical composition comprising a compound of the general formula (IM), general formula (I), general formula (II-1), general formula (II-2), general formula (III-1), general formula (III-1-A), general formula (III-2) and shown in Table A, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0179] This disclosure further relates to the use of compounds of general formula (IM), general formula (I), general formula (II-1), general formula (II-2), general formula (III-1), general formula (III-1-A), general formula (III-2) and those shown in Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising thereof, in the preparation of PARP1 inhibitors.
[0180] This disclosure further relates to the use of compounds of general formula (IM), general formula (I), general formula (II-1), general formula (II-2), general formula (III-1), general formula (III-1-A), general formula (III-2) and those shown in Table A, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising thereof, in the preparation of medicaments for the treatment and / or prevention of cancer.
[0181] This disclosure further relates to a method of inhibiting PARP1, comprising administering to a desired patient an effective amount of a compound of formula (IM), formula (I), formula (II-1), formula (II-2), formula (III-1), formula (III-1-A), formula (III-2), and the compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound.
[0182] This disclosure further relates to a method of treating and / or preventing cancer, comprising administering to a desired patient a therapeutically effective amount of a compound of formula (IM), formula (I), formula (II-1), formula (II-2), formula (III-1), formula (III-1-A), formula (III-2), and the compound shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
[0183] This disclosure further relates to a compound of general formula (IM), general formula (I), general formula (II-1), general formula (II-2), general formula (III-1), general formula (III-1-A), general formula (III-2) and shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof, which is used as a medicine.
[0184] This disclosure further relates to a compound of general formula (IM), general formula (I), general formula (II-1), general formula (II-2), general formula (III-1), general formula (III-1-A), general formula (III-2) and shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the thereof, which is used as a PARP1 inhibitor.
[0185] This disclosure further relates to a compound of general formula (IM), general formula (I), general formula (II-1), general formula (II-2), general formula (III-1), general formula (III-1-A), general formula (III-2) and shown in Table A, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof, for use in the treatment and / or prevention of cancer.
[0186] The cancers described in this disclosure are selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer (such as colon cancer and rectal cancer), lung cancer, kidney cancer, liver cancer (such as hepatocellular carcinoma), cervical cancer, endometrial cancer, myeloma (such as multiple myeloma), leukemia (such as acute leukemia, chronic leukemia, myeloid leukemia, myelofibrosis, erythroleukemia), lymphoma (such as diffuse large B-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, T-cell or B-cell lymphoid malignancies, follicular lymphoma), acoustic neuroma, basal cell carcinoma, bile duct cancer, bladder cancer, brain cancer, bronchial cancer, sarcoma (such as chondrosarcoma, fibrosarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, myxosarcoma, osteoblastic sarcoma, rhabdomyosarcoma). The cancers include, but are not limited to, chordoma, choriocarcinoma, craniopharyngioma, cystadenocarcinoma, embryonal carcinoma, hemangioendothelioma, ependymoma, epithelial carcinoma, esophageal cancer (also known as esophageal cancer), primary thrombocytosis, Ewing's tumor, testicular cancer, glioma, heavy chain disease, angioblastoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, neuroblastoma, midline carcinoma of NUT, glioma, bone cancer, nasopharyngeal carcinoma, oral cancer, thyroid cancer, pineal tumor, polycythemia vera, retinoblastoma, sebaceous gland carcinoma, seminoma, skin cancer, squamous cell carcinoma, synovoma, sweat gland carcinoma, Waldenström macroglobulinemia, and Wilms' tumor; preferably, the cancers are selected from breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer, and lung cancer.
[0187] The active compounds can be formulated into forms suitable for administration via any appropriate route, using one or more pharmaceutically acceptable carriers through conventional methods. Therefore, the active compounds of this disclosure can be formulated into various dosage forms for oral administration, injection (e.g., intravenous, intramuscular, or subcutaneous), inhalation, or blow-through administration. The compounds of this disclosure can also be formulated into dosage forms such as tablets, hard or soft capsules, aqueous or oily suspensions, emulsions, injections, dispersible powders or granules, suppositories, lozenges, or syrups.
[0188] As a general guideline, the active compound is preferably expressed in a unit dose manner, or in a manner that allows the patient to self-administer a single dose. The unit dose of the disclosed compound or composition may be expressed as a tablet, capsule, sachet, bottled liquid, powder, granule, lozenge, suppository, regenerated powder, or liquid formulation. Suitable unit doses may range from 0.1 to 1000 mg.
[0189] In addition to the active compound, the pharmaceutical compositions disclosed herein may contain one or more excipients selected from the following: fillers (diluents), binders, wetting agents, disintegrants, or excipients. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the active compound.
[0190] Tablets contain an active ingredient and non-toxic, pharmaceutically acceptable excipients suitable for tablet preparation, used for mixing. These excipients may be inert excipients, granulating agents, disintegrants, binders, and lubricants. These tablets may be uncoated or coated using known techniques that mask the taste of the drug or delay disintegration and absorption in the gastrointestinal tract, thus providing sustained release over a longer period.
[0191] Oral formulations can also be provided using soft gelatin capsules in which the active ingredient is mixed with an inert solid diluent or in which the active ingredient is mixed with a water-soluble carrier or an oil solvent.
[0192] Aqueous suspensions contain active substances and excipients suitable for preparing aqueous suspensions, used for mixing. These excipients are suspending agents, dispersing agents, or wetting agents. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweeteners.
[0193] Oil suspensions are prepared by suspending the active ingredient in vegetable or mineral oil. Oil suspensions may contain thickeners. Sweeteners and flavoring agents mentioned above may be added to provide palatable formulations. These compositions may be preserved by adding antioxidants.
[0194] The pharmaceutical compositions disclosed herein may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, a mineral oil, or a mixture thereof. Suitable emulsifiers may be naturally occurring phospholipids, and the emulsion may also contain sweeteners, flavoring agents, preservatives, and antioxidants. Such formulations may also contain modifiers, preservatives, colorants, and antioxidants.
[0195] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous solutions. Acceptable solvents or media that can be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in the oil phase, which can be injected into the patient's bloodstream via local large-volume injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compounds disclosed herein. To maintain such a constant concentration, a continuous intravenous delivery device can be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous infusion pump.
[0196] The pharmaceutical compositions disclosed herein may be in the form of sterile injectable aqueous or oil suspensions for intramuscular and subcutaneous administration. These suspensions may be formulated using suitable dispersants or wetting agents and suspending agents as described above, according to known techniques. The sterile injectable formulations may also be sterile injectable solutions or suspensions prepared in parenteral-acceptable, non-toxic diluents or solvents. Furthermore, sterile fixative oils may be conveniently used as solvents or suspension media. For this purpose, any blended fixative oil may be used. Additionally, fatty acids may also be used to prepare injectable formulations.
[0197] The disclosed compounds can be administered in suppository form for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable, non-irritating excipient that is solid at normal temperatures but liquid in the rectum, and thus dissolves in the rectum to release the drug.
[0198] The compounds disclosed herein can be administered by adding water to prepare water-soluble dispersible powders and granules. These pharmaceutical compositions can be prepared by mixing the active ingredient with a dispersant or wetting agent, a suspending agent, or one or more preservatives.
[0199] As is well known to those skilled in the art, the dosage of a drug depends on a variety of factors, including but not limited to: the activity of the specific compound used, the patient's age, the patient's weight, the patient's health status, the patient's behavior, the patient's diet, the timing of administration, the route of administration, the rate of excretion, the combination of drugs, the severity of the disease, etc.; in addition, the optimal treatment mode, such as the treatment pattern, the daily dosage of the compound, or the type of medicinal salt can be validated based on conventional treatment protocols.
[0200] Terminology Explanation
[0201] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0202] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably an alkyl group having 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C12). 1-12 Alkyl groups, more preferably alkyl groups having 1 to 6 carbon atoms (i.e., C1646-C ... 1-6Alkyl groups. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl. 4-Methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and their various branched isomers, etc. Alkyl groups can be substituted or unsubstituted, and when substituted, they can be substituted at any usable connection point. The substituents are optionally selected from one or more of the following: D atom, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0203] The term "alkylene" refers to a saturated straight-chain or branched aliphatic hydrocarbon group, which is a residue derived from a parent alkane by removing two hydrogen atoms from the same carbon atom or two different carbon atoms. It is a straight-chain or branched group containing 1 to 20 carbon atoms, preferably having 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C64). 1-12 Alkylenes, more preferably alkylenes having 1 to 6 carbon atoms (i.e., C16-164 ... 1-6Alkylenes. Non-limiting examples of alkylenes include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), etc. Alkylenes can be substituted or unsubstituted, and when substituted, they can be substituted at any usable linking point, with substituents optionally selected from one or more of alkenyl, alkynyl, alkoxy, haloalkoxy, cycloalkyloxy, heterocyclic alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkoxy, heterocyclic alkoxy, cycloalkylthio, heterocyclic alkylthio, and oxo.
[0204] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in a molecule, wherein the definition of alkyl is as described above, and preferably an alkenyl group having 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C14). 2-12 Alkenyl), more preferably alkenyl groups having 2 to 6 carbon atoms (i.e., C14-C ... 2-6 Alkenyl). Non-limiting examples include vinyl, propenyl, isopropenyl, butenyl, etc. Alkenyl groups can be substituted or unsubstituted, and when substituted, the substituent is preferably selected from one or more substituents selected from alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0205] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in a molecule, as defined above. Preferably, it has 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., C64). 2-12 Alkyne group), more preferably alkynyl group having 2 to 6 carbon atoms (i.e., C12-C6 ... 2-6 (Alynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentyynyl, hexynyl, etc. The alkynyl group can be substituted or unsubstituted, and when substituted, the substituent is preferably selected from one or more of alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0206] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms (i.e., 3 to 12-membered cycloalkyl), more preferably 3 to 8 carbon atoms (i.e., 3 to 8-membered cycloalkyl), and more preferably 3 to 6 carbon atoms (i.e., 3 to 6-membered cycloalkyl). Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclohepttrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes spirocycloalkyl, fused cycloalkyl, and bridged cycloalkyl.
[0207] The term "spirocycloalkyl" refers to a polycyclic group consisting of 5 to 20 quintiles, sharing a single carbon atom (called a spiro atom) between the rings, and may contain one or more double bonds. Preferably, it is 6 to 14 quintiles, more preferably 7 to 10 quintiles (e.g., 7, 8, 9, or 10 quintiles). Spirocycloalkyl groups are classified as monospirocycloalkyl or polyspirocycloalkyl (e.g., bispirocycloalkyl) based on the number of shared spiro atoms between the rings, with monospirocycloalkyl and bispirocycloalkyl being preferred. More preferably, it is a 3 / 4 quintile, 3 / 5 quintile, 3 / 6 quintile, 4 / 4 quintile, 4 / 5 quintile, 4 / 6 quintile, 5 / 3 quintile, 5 / 4 quintile, 5 / 5 quintile, 5 / 6 quintile, 5 / 7 quintile, 6 / 3 quintile, 6 / 4 quintile, 6 / 5 quintile, 6 / 6 quintile, 6 / 7 quintile, 7 / 5 quintile, or 7 / 6 quintile monospirocycloalkyl. Non-limiting examples of spirocycloalkyl groups include:
[0208]
[0209] The term "fused cycloalkyl" refers to a 5- to 20-membered polycyclic aromatic hydrocarbon group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered). Depending on the number of constituent rings, it can be classified as bicyclic or polycyclic (e.g., tricyclic, tetracyclic) fused cycloalkyl, preferably bicyclic or tricyclic fused cycloalkyl, more preferably 3- / 4-membered, 3- / 5-membered, 3- / 6-membered, 4- / 4-membered, 4- / 5-membered, 4- / 6-membered, 5- / 3-membered, 5- / 4-membered, 5- / 5-membered, 5- / 6-membered, 5- / 7-membered, 6- / 3-membered, 6- / 4-membered, 6- / 5-membered, 6- / 6-membered, 6- / 7-membered, 7- / 5-membered, or 7- / 6-membered bicyclic fused cycloalkyl. Non-limiting examples of fused cycloalkyl groups include:
[0210]
[0211] The term "bridged cycloalkyl" refers to a 5- to 20-membered polycyclic carbon group in which any two rings share two non-directly bonded carbon atoms, and may contain one or more double bonds. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered). Depending on the number of rings, it can be classified as bicyclic or polycyclic (e.g., tricyclic, tetracyclic) bridged cycloalkyl, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:
[0212]
[0213] The cycloalkyl ring comprises a cycloalkyl group (including monocyclic, spirocyclic, fused, and bridged rings) fused to an aryl, heteroaryl, or heterocyclic alkyl ring as described above, wherein the ring attached to the parent structure is a cycloalkyl group. Non-limiting examples include... etc.; preferably
[0214] The cycloalkyl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected independently from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0215] The term "alkoxy" refers to -O-(alkyl), where alkyl is defined as described above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy. Alkoxy groups can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably selected from D atoms, halogens, alkoxy groups, haloalkyl groups, haloalkoxy groups, cycloalkyloxy groups, heterocyclic oxy groups, hydroxyl groups, hydroxyalkyl groups, cyano groups, amino groups, nitro groups, cycloalkyl groups, heterocyclic groups, aryl groups, and heteroaryl groups.
[0216] The term "heterocyclic group" refers to a saturated or partially unsaturated monocyclic or polycyclic substituent containing 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) ring atoms (i.e., 3 to 20 membered heterocyclic groups), wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxides or sulfones), but does not include the -OO-, -OS-, or -SS- ring moiety, and the remaining ring atoms are carbon. Preferably, it comprises 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) ring atoms (i.e., 3 to 12-membered heterocyclic groups), wherein 1 to 4 (e.g., 1, 2, 3, and 4) are heteroatoms; more preferably, it comprises 3 to 8 ring atoms (e.g., 3, 4, 5, 6, 7, and 8) (i.e., 3 to 8-membered heterocyclic groups), wherein 1 to 3 are heteroatoms (e.g., 1, 2, and 3); even more preferably, it comprises 3 to 6 ring atoms, wherein 1 to 3 are heteroatoms; most preferably, it comprises 5 or 6 ring atoms, wherein 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and homopiperazinyl. Polycyclic heterocyclic groups include spiroheterocyclic, fused heterocyclic, and bridged heterocyclic groups.
[0217] The term "spiroheterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which one or more ring atoms share a single atom (called a spiro atom), wherein the sulfur may optionally be oxidized (i.e., forming a sulfoxide or sulfone), and the remaining ring atoms are carbon. It may contain one or more double bonds. Preferably, it is 6- to 14-membered (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14-membered) (i.e., 6- to 14-membered spiroheterocyclic groups), more preferably 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered spiroheterocyclic groups). Spiroheterocyclic groups are classified into monospiroheterocyclic groups or polyspiroheterocyclic groups (e.g., bispiroheterocyclic groups) according to the number of shared spiro atoms between the rings, with monospiroheterocyclic groups and bispiroheterocyclic groups being more preferred. More preferably, they are 3 / 4, 3 / 5, 3 / 6, 4 / 4, 4 / 5, 4 / 6, 5 / 3, 5 / 4, 5 / 5, 5 / 6, 5 / 7, 6 / 3, 6 / 4, 6 / 5, 6 / 6, 6 / 7, 7 / 5, or 7 / 6 monospirocyclic heterocyclic groups. Non-limiting examples of spirocyclic groups include:
[0218]
[0219] The term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system. One or more rings may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is a 6- to 14-membered group (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14-membered group) (i.e., a 6- to 14-membered fused heterocyclic group), more preferably a 7- to 10-membered group (e.g., 7, 8, 9, or 10-membered group) (i.e., a 7- to 10-membered fused heterocyclic group). Based on the number of constituent rings, fused heterocyclic groups can be classified into bicyclic or multicyclic (e.g., tricyclic, tetracyclic) fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 5-membered / 7-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered, or 7-membered / 6-membered bicyclic fused heterocyclic groups. Non-limiting examples of fused heterocyclic groups include:
[0220]
[0221] The term "bridged heterocyclic group" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two non-directly connected atoms. It may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the sulfur may optionally be oxidized (i.e., forming a sulfoxide or sulfone), and the remaining ring atoms are carbon. Preferably, it is a 6- to 14-membered (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14-membered) (i.e., 6- to 14-membered bridged heterocyclic group), more preferably a 7- to 10-membered (e.g., 7, 8, 9, or 10-membered) (i.e., 7- to 10-membered bridged heterocyclic group). Depending on the number of constituent rings, it can be classified as a bicyclic or polycyclic (e.g., tricyclic, tetracyclic) bridged heterocyclic group, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
[0222]
[0223] The heterocyclic ring comprises a heterocyclic group (including monocyclic, spirocyclic, fused heterocyclic, and bridged heterocyclic rings) fused to an aryl, heteroaryl, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heterocyclic group, and non-limiting examples include:
[0224] wait.
[0225] The heterocyclic group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0226] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic) group having a conjugated π-electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. The aryl ring comprises an aryl ring fused to a heteroaryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring attached to the parent structure is an aryl ring, and non-limiting examples include:
[0227]
[0228] The aryl group can be substituted or unsubstituted, and when substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl, and heteroaryl.
[0229] The term "heteroaryl" refers to a heteroaryl system comprising 1 to 4 heteroatoms (e.g., 1, 2, 3, and 4) and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. The heteroaryl is preferably 5 to 10-membered (e.g., 5, 6, 7, 8, 9, or 10-membered) (i.e., 5 to 10-membered heteroaryl), more preferably 5- or 6-membered, such as furanyl, thiophene, pyridinyl, pyrroleyl, N-alkylpyrroleyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc. The heteroaryl ring comprises a heteroaryl ring fused to an aryl, heterocyclic, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include:
[0230]
[0231]
[0232] The heteroaryl group can be substituted or unsubstituted. When substituted, it can be substituted at any usable connection point. The substituent is preferably selected from one or more substituents selected from halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclic oxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclic, aryl and heteroaryl.
[0233] The aforementioned cycloalkyl, heterocyclic, aryl, and heteroaryl residues include residues derived from removing one hydrogen atom from a parent ring atom, or residues derived from removing two hydrogen atoms from the same ring atom or two different ring atoms of the parent, namely "divalent cycloalkyl", "divalent heterocyclic", "aryl", and "heteroaryl".
[0234] The term "amino protecting group" is used to protect the amino group by a group that is easily removed, so that the amino group remains unchanged when other parts of the molecule react. Non-limiting examples include (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butoxycarbonyl, acetyl, benzyl, allyl, and p-methoxybenzyl, etc. These groups may optionally be replaced by 1 to 3 substituents selected from halogens, alkoxy groups, and nitro groups.
[0235] The term "hydroxyl protecting group" refers to a hydroxyl derivative that is typically used to block or protect the hydroxyl group in a reaction on other functional groups of a compound. As an example, preferably, the hydroxyl protecting group can be triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl (TBS), tert-butyldiphenylsilyl, methyl, tert-butyl, benzyl, methoxymethyl (MOM), ethoxyethyl, formyl, acetyl, benzoyl, or p-nitrobenzoyl.
[0236] The term “cycloalkyloxy” refers to cycloalkyl-O-, where the cycloalkyl group is as defined above.
[0237] The term “heterocyclic oxy group” refers to the heterocyclic group -O-, where the heterocyclic group is as defined above.
[0238] The term "aryloxy group" refers to aryl-O-, where the aryl group is as defined above.
[0239] The term “heteroaryloxy” refers to heteroaryl-O-, where the heteroaryl group is as defined above.
[0240] The term "alkylthio" refers to alkyl-S-, where the alkyl group is as defined above.
[0241] The term "halogenated alkyl" refers to an alkyl group that has been substituted with one or more halogens, wherein the alkyl group is as defined above.
[0242] The term "haloalkoxy" refers to an alkoxy group that is substituted by one or more halogens, wherein the alkoxy group is as defined above.
[0243] The term “deuterated alkyl” refers to an alkyl group that is replaced by one or more deuterium atoms, wherein the alkyl group is as defined above.
[0244] The term "hydroxyalkyl" refers to an alkyl group that is replaced by one or more hydroxyl groups, wherein the alkyl group is as defined above.
[0245] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0246] The term "hydroxyl group" refers to -OH.
[0247] The term "thiol" refers to -SH.
[0248] The term "amino" refers to -NH2.
[0249] The term "cyano" refers to -CN.
[0250] The term "nitro" refers to -NO2.
[0251] The term "oxo" or "oxo" refers to "=O".
[0252] The term "carbonyl" refers to C=O.
[0253] The term "carboxyl group" refers to -C(O)OH.
[0254] The term "carboxylic acid ester group" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O- or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.
[0255] The compounds disclosed herein can exist in specific stereoisomer forms. The term "stereoisomer" refers to isomers with the same structure but different spatial arrangements of atoms. These include cis and trans (or Z and E) isomers, (-)- and (+)- isomers, (R)- and (S)- enantiomers, diastereomers, (D)- and (L)- isomers, tautomers, blocked isomers, conformational isomers, and mixtures thereof (such as racemic mixtures and mixtures of diastereomers). Substituents in the compounds disclosed herein may contain additional asymmetric atoms. All such stereoisomers and mixtures thereof are included within the scope of this disclosure. Optically active (-)- and (+)- isomers, (R)- and (S)- enantiomers, and (D)- and (L)- isomers can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. This disclosure discloses an isomer of a compound, which can be prepared by asymmetric synthesis or with chiral auxiliaries, or, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), by forming a salt of the diastereomer with a suitable optically active acid or base, followed by diastereomer resolution using conventional methods known in the art to obtain the pure isomer. Furthermore, the separation of enantiomers and diastereomers is typically performed by chromatography.
[0256] The compounds disclosed herein can exist in various tautomer forms, and all such forms are included within the scope of this disclosure. The terms "tautomer" or "tautomer form" refer to a structural isomer that exists in equilibrium and readily transforms from one isomer to another. This includes all possible tautomers, i.e., existing as a single isomer or as a mixture of said tautomers in any proportion. Non-limiting examples include: keto-enols, imine-enamines, lactam-lactamimides, etc. An example of a lactam-lactamimide in equilibrium is shown below:
[0257]
[0258] When referring to the pyrazolyl group, it should be understood to include any one or a mixture of two tautomers of the following two structures:
[0259]
[0260] All tautomers are within the scope of this disclosure, and the naming of compounds does not exclude any tautomers.
[0261] The compounds disclosed herein include their isotopic derivatives. The term "isotopic derivative" refers to a compound whose structure differs only in the presence of one or more isotopically enriched atoms. For example, compounds having the structure disclosed herein, using "deuterium" or "tritium" instead of hydrogen, or using... 18 F-fluorine labeling ( 18 F isotopes) can be used instead of fluorine, or... 11 C-、 13 C- or 14 C-enriched carbon ( 11 C-、 13 C- or 14 C-carbon labeling; 11 C-、 13 C- or 14Compounds in which carbon atoms are replaced by C-isotopes are within the scope of this disclosure. Such compounds can be used as analytical tools or probes in biological assays, or as in vivo diagnostic imaging tracers for diseases, or as tracers for pharmacodynamic, pharmacokinetic, or receptor studies. In the deuterated form, each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize the deuterated form of the compound with reference to relevant literature. Commercially available deuteration starting materials can be used in the preparation of the deuterated form of the compound, or they can be synthesized using conventional techniques with deuteration reagents, including but not limited to deuterated boranes, trideuterated borane tetrahydrofuran solutions, deuterated lithium aluminum hydride, deuterated iodoethane, and deuterated iodomethane. Deuterated compounds generally retain activity comparable to undeuterated compounds, and better metabolic stability can be achieved when deuterated at certain specific sites, thus providing certain therapeutic advantages. Compared to undeuterated drugs, deuterated drugs offer advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged biological half-life. All isotopic variations of the compounds disclosed herein, regardless of radioactivity, are included within the scope of this disclosure. Each available hydrogen atom bonded to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium substitution can be partial or complete; partial deuterium substitution refers to the replacement of at least one hydrogen atom with at least one deuterium atom.
[0262] In the chemical structure of the compounds described in this disclosure, the bonds... This indicates that the configuration is not specified; that is, if chiral isomers exist in the chemical structure, the bond... It can be Or simultaneously include Two configurations.
[0263] "Optional" or "optional" means that the event or situation subsequently described may, but does not have to, occur; the description includes the possibility or possibility that the event or situation may or may not occur. For example, "optionally halogenated or cyano-substituted C..." 1-6 "Alkyl" means that halogens or cyano groups may or may not be present. This description includes cases where alkyl groups are substituted by halogens or cyano groups and cases where alkyl groups are not substituted by halogens or cyano groups.
[0264] "Substituted" refers to one or more hydrogen atoms in a group, preferably 1 to 5, more preferably 1 to 3 hydrogen atoms, which are independently substituted by the corresponding number of substituents. Those skilled in the art can determine possible or impossible substitutions without much effort (through experimentation or theory). For example, an amino or hydroxyl group with free hydrogen may be unstable when combined with a carbon atom having an unsaturated bond (such as an alkene).
[0265] "Pharmaceutical composition" means a mixture containing one or more of the compounds described herein or their pharmaceutically acceptable salts or prodrugs, along with other chemical components, such as pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to a living organism, thereby promoting the absorption of the active ingredient and its biological activity.
[0266] "Pharmacologically acceptable salt" refers to the salt of the compounds disclosed herein, which may be selected from inorganic or organic salts. Such salts are safe and effective when used in mammals and possess the expected biological activity. The salt can be prepared separately during the final isolation and purification of the compound, or by reacting a suitable group with a suitable base or acid. Bases commonly used to form pharmaceutically acceptable salts include inorganic bases, such as sodium hydroxide and potassium hydroxide, and organic bases, such as ammonia. Acids commonly used to form pharmaceutically acceptable salts include both inorganic and organic acids.
[0267] For the purposes of pharmaceuticals or pharmacologically active agents, the term "therapeutic effective amount" refers to the amount of a drug or agent sufficient to achieve or at least partially achieve the intended effect. The determination of the effective amount varies from person to person, depending on the recipient's age and general condition, as well as the specific active substance. The appropriate effective amount in a particular case can be determined by a person skilled in the art based on routine testing.
[0268] As used herein, the term "pharmaceutically acceptable" means that these compounds, materials, compositions, and / or dosage forms are suitable for contact with patient tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, within reasonable medical judgment, have a reasonable benefit / risk ratio, and are effective for their intended use.
[0269] As used herein, the singular forms of “a,” “an,” and “the” include plural references, and vice versa, unless the context clearly indicates otherwise.
[0270] When the term "about" is applied to parameters such as pH, concentration, temperature, etc., it indicates that the parameter can vary by ±10%, and sometimes more preferably within ±5%. As those skilled in the art will understand, when a parameter is not critical, figures are usually given for illustrative purposes only, not as limitations.
[0271] The method for synthesizing the compounds disclosed herein
[0272] In order to achieve the purpose of this disclosure, the following technical solution is adopted:
[0273] Option 1
[0274] This disclosure discloses a method for preparing a compound of formula (IM) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0275]
[0276] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (IMb) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (IM) or a pharmaceutically usable salt thereof.
[0277] in:
[0278] L is a halogen, preferably a chlorine atom;
[0279] X, Y, G 1 To G 3 R 0 To R 3 , s and t are as defined in the general formula (IM).
[0280] Option 2
[0281] The present disclosure discloses a method for preparing the compound of formula (I) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0282]
[0283] A compound of general formula (IMa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (I) or a pharmaceutically usable salt thereof.
[0284] in:
[0285] L is a halogen, preferably a chlorine atom;
[0286] X, Y, G 1 To G 3 R 1 To R 3 , s and t are as defined in general formula (I).
[0287] Option 3
[0288] This disclosure discloses a method for preparing the compound of formula (II-1) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0289]
[0290] A compound of general formula (II-1a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (II-1) or a pharmaceutically usable salt thereof.
[0291] in:
[0292] L is a halogen, preferably a chlorine atom;
[0293] X, G 1 To G 3 R 1 To R 3 , s, t and n are as defined in general formula (II-1).
[0294] Option 4
[0295] This disclosure discloses a method for preparing the compound of formula (II-2) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0296]
[0297] A compound of general formula (II-2a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (V) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (II-2) or a pharmaceutically usable salt thereof.
[0298] in:
[0299] L is a halogen, preferably a chlorine atom;
[0300] X, G 1 To G 3 R 1 To R 3 R 5 , s, t and r are as defined in general formula (II-2).
[0301] Option 5
[0302] This disclosure discloses a method for preparing the compound of formula (III-1) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0303]
[0304] A compound of general formula (III-1a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (VI) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (III-1) or a pharmaceutically usable salt thereof.
[0305] in:
[0306] m1 is 0 or 1;
[0307] L is a halogen, preferably a chlorine atom;
[0308] R 1 R 6 R 7a R 7b And n is as defined in general formula (III-1).
[0309] Option Six
[0310] This disclosure includes a method for preparing the compound of formula (III-1-A) or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0311]
[0312] A compound of general formula (III-1-Aa) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (VI) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (III-1-A) or a pharmaceutically usable salt thereof.
[0313] in:
[0314] m1 is 0 or 1;
[0315] L is a halogen, preferably a chlorine atom;
[0316] R 1 R 6 R 7a R 7b And n is as defined in general formula (III-1-A).
[0317] Option 7
[0318] This disclosure discloses a method for preparing the compound of formula (III-2) or a pharmaceutically acceptable salt thereof, the method comprising the following steps:
[0319]
[0320] A compound of general formula (III-2a) or a salt thereof (preferably a hydrochloride salt) undergoes a nucleophilic substitution reaction with a compound of general formula (VI) under basic conditions, optionally in the presence of a catalyst, to give a compound of general formula (III-2) or a pharmaceutically usable salt thereof.
[0321] in:
[0322] L is a halogen, preferably a chlorine atom;
[0323] X, R 1 R 5 R 6 R 7a and R 7b As defined in general formula (III-2).
[0324] The reagents providing alkaline conditions include organic and inorganic bases. The organic bases include, but are not limited to, triethylamine, N,N-diisopropylethylamine, n-butyllithium, diisopropylaminolithium, sodium acetate, potassium acetate, sodium ethoxide, sodium tert-butoxide, and potassium tert-butoxide, with N,N-diisopropylethylamine being preferred. The inorganic bases include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide monohydrate, lithium hydroxide, and potassium hydroxide.
[0325] The catalyst for the above nucleophilic substitution reaction is sodium iodide or potassium iodide, preferably sodium iodide.
[0326] The above reaction is preferably carried out in a solvent, which includes, but is not limited to: N-methylpyrrolidone, ethylene glycol dimethyl ether, acetic acid, methanol, ethanol, acetonitrile, n-butanol, toluene, tetrahydrofuran, dichloromethane, petroleum ether, ethyl acetate, n-hexane, dimethyl sulfoxide, 1,4-dioxane, water, N,N-dimethylformamide, N,N-dimethylacetamide, 1,2-dibromoethane, and mixtures thereof. Detailed Implementation
[0327] The following embodiments are used to further describe this disclosure, but these embodiments are not intended to limit the scope of this disclosure.
[0328] Example
[0329] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10⁻¹⁰. -6 The unit (ppm) is given. NMR determination was performed using a Bruker AVANCE-400 NMR spectrometer or a Bruker AVANCE NEO 500M. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), and deuterated methanol (CD3OD). The internal standard was tetramethylsilane (TMS).
[0330] MS measurements were performed using an Agilent 1200 / 1290DAD-6110 / 6120 Quadrupole MS liquid chromatography-mass spectrometry system (manufacturer: Agilent, MS model: 6110 / 6120 Quadrupole MS).
[0331] waters ACQuity UPLC-QD / SQD (Manufacturer: waters, MS model: waters ACQuityQdaDetector / waters SQ Detector) THERMO Ultimate 3000-Q Exactive (Manufacturer: THERMO, MS model: THERMO Q Exactive).
[0332] High-performance liquid chromatography (HPLC) analysis was performed using an Agilent HPLC 1200DAD, an Agilent HPLC 1200VWD, and a Waters HPLC e2695-2489 liquid chromatograph.
[0333] Chiral HPLC analysis was performed using an Agilent 1260 DAD high-performance liquid chromatograph.
[0334] High performance liquid chromatography (HPLC) was performed using Waters 2545-2767, Waters 2767-SQ Detecor2, Shimadzu LC-20AP, and Gilson GX-281 preparative chromatographs.
[0335] Chiral preparation was performed using a Shimadzu LC-20AP preparative chromatograph.
[0336] The CombiFlash rapid preparation system uses a CombiFlash Rf200 (TELEDYNE ISCO).
[0337] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.
[0338] Silica gel column chromatography generally uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.
[0339] Mean inhibition rate of kinases and IC 50 The values were determined using a NovoStar microplate reader (BMG GmbH, Germany).
[0340] The known starting materials disclosed herein can be synthesized using or in accordance with methods known in the art, or can be purchased from companies such as ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, and Darui Chemicals.
[0341] Unless otherwise specified in the examples, all reactions can be carried out under an argon or nitrogen atmosphere.
[0342] Argon or nitrogen atmosphere refers to a reaction flask connected to an argon or nitrogen gas balloon with a volume of approximately 1L.
[0343] A hydrogen atmosphere refers to a reaction flask connected to a hydrogen balloon with a volume of approximately 1L.
[0344] The pressurized hydrogenation reaction was performed using a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or an HC2-SS hydrogenator.
[0345] The hydrogenation reaction is usually carried out under vacuum, filled with hydrogen gas, and repeated 3 times.
[0346] The microwave reaction was performed using a CEM Discover-S 908860 microwave reactor.
[0347] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.
[0348] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.
[0349] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent used in the reaction, the eluent system for column chromatography used to purify the compounds, and the developing solvent system for TLC included: A: dichloromethane / methanol system. The volume ratio of the solvent was adjusted according to the polarity of the compounds. Small amounts of basic or acidic reagents such as triethylamine and acetic acid could also be added for adjustment.
[0350] Example 1
[0351] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-8-carboxamide 1
[0352]
[0353] first step
[0354] methyl 5-bromo-6-fluoropyridinecarboxylate 1b
[0355] 5-bromopyridine-2-carboxylic acid methyl ester 1a (2.0 g, 9.25 mmol, Shanghai Shaoyuan) was dissolved in acetonitrile (50 mL), and silver difluoride (4.7 g, 32.22 mmol) was added. The mixture was stirred under a nitrogen atmosphere for 14 hours. The reaction solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give title compound 1b (1.8 g, yield: 83%).
[0356] MS m / z(ESI):233.9[M+1].
[0357] Step 2
[0358] (±)-3-(((tert-butyldimethylsilyl)oxy)methyl)piperazine-1-carboxylic acid tert-butyl ester 1d
[0359] Compound (±)-3-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester 1c (2 g, 9.24 mmol, Shanghai Bide) was dissolved in dichloromethane (30 mL), and imidazole (1.3 g, 19.09 mmol) and tert-butyldimethylchlorosilane (2.17 g, 14.39 mmol) were added. The mixture was stirred for 1 hour, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 1d (1.9 g, yield: 62.1%).
[0360] MS m / z(ESI): 331.2 [M+1].
[0361] Step 3
[0362] (±)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(2-fluoro-6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester 1e
[0363] Compound 1b (300 mg, 1.28 mmol) and compound 1d (635 mg, 1.92 mmol) were dissolved in 1,4-dioxane (15 mL), and methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (107 mg, 127.78 μmol) and cesium carbonate (1.0 g, 3.06 mmol) were added. The reaction was carried out at 110 °C for 14 hours under a nitrogen atmosphere. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give title compound 1e (290 mg, yield: 46.7%).
[0364] MS m / z(ESI):484.2[M+1].
[0365] Step 4
[0366] (±)-3-(tert-butyl)-8-methyl1,2,4a,5-tetrahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-3,8(4H)-dicarboxylic acid ester 1f
[0367] Compound 1e (290 mg, 599.61 μmol) was dissolved in tetrahydrofuran (6 mL), and 3 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution was added. The mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 1f (200 mg, yield: 95.2%). The product was used directly in the next reaction without purification.
[0368] MS m / z(ESI): 350.2 [M+1].
[0369] Step 5
[0370] (±)-8-(methylaminocarbonyl)-1,2,4a,5-tetrahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester 1g
[0371] The crude product compound 1f (200 mg, 572.44 μmol) was dissolved in ethanol (5 mL), and 1.13 mL of 1 M methylamine in ethanol was added. The mixture was stirred for 14 hours, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give the title compound 1 g (190 mg, yield: 95.4%).
[0372] MS m / z(ESI): 349.2 [M+1].
[0373] Step 6
[0374] (±)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-8-carboxamide hydrochloride 1h
[0375] 1 g (50 mg, 143.5 μmol) of compound was dissolved in 2 mL of dioxane, and 1 mL of 4 M dioxane hydrochloride solution was added. The mixture was stirred and reacted for 0.5 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 1h (35 mg, yield: 98.2%). The product was used directly in the next reaction without purification.
[0376] MS m / z(ESI):249.2[M+1].
[0377] Step 7
[0378] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-8-carboxamide 1
[0379] The crude compound 1h (30 mg, 134.72 μmol), compound 7-(chloromethyl)-3-ethyl-1,5-naphthid-2(1H)-one 1i (33 mg, 132.91 μmol, prepared by the method disclosed in Example 4 on page 15 of patent application "WO2021013735A1"), N,N-diisopropylethylamine (174 mg, 1.34 mmol), and sodium iodide (4 mg, 26.68 μmol) were dissolved in acetonitrile (3 mL). The mixture was reacted at 80 °C for 3 hours. After the reaction solution was concentrated under reduced pressure, the crude product was subjected to high performance liquid chromatography (Waters-2545, column: SharpSil-T) for 3 hours. C18, 30*150mm, 5μm; mobile phase: aqueous phase (10mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30mL / min) to obtain title compound 1 (4mg, yield: 6.8%).
[0380] MS m / z(ESI):435.2[M+1].
[0381] 1 H NMR (500MHz, CDCl3): δ10.11(s,1H),8.53(d,1H),7.86(s,1H),7.81(d,1H),7.61(d ,1H),7.58-7.54(m,1H),7.10(d,1H),4.37(dd,1H),4.17(dd,1H),3.76(d,1H),3.7 3-3.65(m,2H),3.40-3.30(m,1H),3.09-3.02(m,1H),2.99(d,2H),2.89(dt,1H),2. 80-2.68(m,2H),2.41(td,1H),2.25(t,1H),2.03(d,1H),1.98(t,1H),1.33(t,3H).
[0382] Example 2
[0383] (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazine-8-carboxamide 2
[0384]
[0385] first step
[0386] (R)-3-(((tert-butyldimethylsilyl)oxy)methyl)piperazine-1-carboxylic acid tert-butyl ester 2b
[0387] Compound (3R)-3-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester 2a (4.2 g, 19.4 mmol, Shanghai Bide) was dissolved in dichloromethane (100 mL), and triethylamine (117 mg, 38.9 mmol), tert-butyldimethylchlorosilane (2.17 g, 14.39 mmol), and 4-dimethylaminopyridine (3.94 g, 0.94 mmol) were added. The mixture was stirred for 14 hours, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to give title compound 2b (6 g, yield: 93%).
[0388] MS m / z(ESI): 331.2 [M+1].
[0389] Step 2
[0390] (R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(2-fluoro-6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester 2c
[0391] Compound 1b (1.3 g, 5.55 mmol) and compound 2b (2.02 g, 6.1 mmol) were dissolved in 1,4-dioxane (15 mL), and methanesulfonic acid (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (464 mg, 554.7 μmol) and cesium carbonate (3.6 g, 11.1 mmol) were added. The reaction was carried out at 110 °C for 14 h under a nitrogen atmosphere. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give title compound 2c (1 g, yield: 37.2%).
[0392] MS m / z(ESI):484.2[M+1].
[0393] Step 3
[0394] 3-(tert-butyl)-8-methyl(R)-1,2,4a,5-tetrahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-3,8(4H)-dicarboxylic acid ester 2d
[0395] Compound 2c (1 g, 2.06 mmol) was dissolved in tetrahydrofuran (6 mL), and 6 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution was added. The mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 2d (722 mg, yield: 99%). The product was used directly in the next reaction without purification.
[0396] MS m / z(ESI): 350.2 [M+1].
[0397] Step 4
[0398] (R)-8-(methylaminocarbonyl)-1,2,4a,5-tetrahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-3(4H)-carboxylic acid tert-butyl ester 2e
[0399] The crude product compound 2d (722 mg, 2.06 mmol) was dissolved in 10 mL of 1 M methylamine in ethanol, and the mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound 2e (700 mg, yield: 97%). The product was used directly in the next step of the reaction without purification.
[0400] MS m / z(ESI): 349.2 [M+1].
[0401] Step 5
[0402] (R)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyridino[2,3-b][1,4]oxazine-8-carboxamide hydrochloride 2f
[0403] Compound 2e (700 mg, 2 mmol) was dissolved in dichloromethane (5 mL), and 2 mL of 4 M dioxane hydrochloride solution was added. The mixture was stirred for 0.5 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 2f (570 mg, yield: 99%). The product was used directly in the next step of the reaction without purification.
[0404] MS m / z(ESI):249.2[M+1].
[0405] Step 6
[0406] (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazine-8-carboxamide 2
[0407] The crude compound 2f (66 mg, 265.82 μmol), compound 1i (60 mg, 269.4 μmol), and N,N-diisopropylethylamine (180.7 mg, 1.4 mmol) were dissolved in acetonitrile (5 mL), and a catalytic amount of sodium iodide was added. The mixture was reacted at 80 °C for 5 hours. After the reaction solution was concentrated under reduced pressure, the crude product was purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to obtain title compound 2 (33 mg, yield: 28.1%).
[0408] MS m / z(ESI):435.2[M+1].
[0409] 1 H NMR (500MHz, CD3OD): δ8.48(d,1H),7.82(s,1H),7.76(d,1H),7.61(d,1H),7.23(d,1H),4.39(dd,1H),4.11(dd,1H),3.84-3 .67(m,3H),3.26(d,1H),3.04(d,1H),2.95(dt,1H),2.89(d,4H),2.66(q,2H),2.41-2.33(m,1H),1.96(t,1H),1.27(t,3H).
[0410] Example 3
[0411] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-9-carboxamide 3
[0412]
[0413] first step
[0414] (±)-3-(hydroxymethyl)-4-(4-methoxybenzyl)piperazine-1-carboxylic acid tert-butyl ester 3a
[0415] Compound 1c (5 g, 23.1 mmol) was dissolved in N,N-dimethylformamide (50 mL), and anhydrous potassium carbonate (4.8 g, 34.7 mmol) and 4-methoxybenzyl chloride (4 g, 25.54 mmol) were added. The mixture was reacted at 60 °C for 72 hours. The reaction solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give title compound 3a (7 g, yield: 90%).
[0416] MS m / z(ESI): 337.2 [M+1].
[0417] Step 2
[0418] (±)-3-(((6-bromo-3-fluoropyridin-2-yl)methoxy)methyl)-4-(4-methoxybenzyl)piperazine-1-carboxylic acid tert-butyl ester 3c
[0419] Compound 6-bromo-2-(bromomethyl)-3-fluoropyridine 3b (1.94 g, 7.21 mmol, prepared by the method disclosed in Preparation Example 6 on page 12 of patent application "WO2016077161A1") and compound 3a (2.2 g, 6.59 mmol) were dissolved in N,N-dimethylformamide (20 mL), sodium hydride (0.36 g, 9 mmol, 60% purity) was added, the reaction was stirred for 1 hour, quenched with water, extracted with dichloromethane (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered to remove the desiccant, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system B to give title compound 3c (1.84 g, yield 53.6%).
[0420] MS m / z(ESI): 524.2 [M+1].
[0421] Step 3
[0422] (±)-3-((3-fluoro-6-(methoxycarbonyl)pyridin-2-yl)methoxy)methyl)-4-(4-methoxybenzyl)piperazine-1-carboxylic acid tert-butyl ester 3d
[0423] Compound 3c (1.84 g, 3.50 mmol) was dissolved in a mixed solvent of N,N-dimethylformamide (3 mL) and ethanol (2 mL), and bis(triphenylphosphine)palladium dichloride (0.55 g, 783.59 μmol) and N,N-diisopropylethylamine (1.1 g, 10.87 mmol) were added. The mixture was stirred at 90 °C for 3 hours under a carbon monoxide atmosphere. After cooling, it was diluted with ethyl acetate (100 mL), washed successively with water and saturated sodium chloride solution, and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 3d (1.1 g, yield: 60.57%).
[0424] MS m / z(ESI): 504.2 [M+1].
[0425] Step 4
[0426] (±)-3-(((3-Fluoro-6-(methoxycarbonyl)pyridin-2-yl)methoxy)methyl)piperazine-1-carboxylic acid tert-butyl ester 3e
[0427] Compound 3d (0.4 g, 772.81 μmol) was dissolved in a mixed solvent of water (3 mL) and acetonitrile (3 mL), and cerium ammonium nitrate (2.11 g, 3.86 mmol) was added. The mixture was purged with hydrogen and stirred for 14 hours. The mixture was then neutralized with saturated sodium bicarbonate aqueous solution (10 mL), filtered, and the filtrate was extracted with ethyl acetate (10 mL × 3). The organic phase was collected, washed with saturated brine, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure to obtain the crude product, title compound 3e (120 mg, yield: 40%).
[0428] MS m / z(ESI): 384.2 [M+1].
[0429] Step 5
[0430] (±)-3-(tert-butyl)9-methyl1,2,4a,5-tetrahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-3,9(4H)-dicarboxylic acid ester 3f
[0431] Compound 3e (300 mg, 754.8 μmol) was dissolved in N,N-dimethylacetamide (2 mL), and N,N-diisopropylethylamine (300 mg, 2.32 mmol) was added. The mixture was reacted in a microwave at 140 °C for 1.5 h. After cooling, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system A to give the title compound 3f (130 mg, yield: 45.6%).
[0432] MS m / z(ESI): 364.2 [M+1].
[0433] The synthetic route in Example 1 was then used, and the starting compound 1f in step 5 was replaced with compound 3f to obtain title compound 3 (7.5 mg, yield: 14.6%).
[0434] MS m / z(ESI):449.2[M+1].
[0435] 1H NMR (500MHz, CD3OD): δ8.51(d,1H),7.93(d,1H),7.86(s,1H),7.79(d,1H),7.50(d,1H),4.99(t,2H),4.85(d,1H),4.08(dd,2H) ,3.87(dd,1H),3.81-3.71(m,2H),3.46(ddd,2H),2.95(s,3H),2.86-2.78(m,1H),2.75-2.61(m,3H),2.57(dd,1H),1.31(t,3H).
[0436] Example 4
[0437] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-d]pyridino[2,3-b][1,4]oxazaheptan-9-carboxamide 4
[0438]
[0439] first step
[0440] (±)-3-(2-((6-bromo-3-fluoropyridin-2-yl)oxy)ethyl)piperazine-1-carboxylic acid tert-butyl ester 4c
[0441] Compound 2,6-dibromo-3-fluoropyridine 4a (1.0 g, 3.92 mmol, Shanghai Bide) and compound (±)-3-(2-hydroxyethyl)piperazine-1-carboxylic acid tert-butyl ester 4b (900 mg, 3.90 mmol, Jiangsu Aikang) were dissolved in tetrahydrofuran (20 mL), and potassium tert-butoxide (880 mg, 7.84 mmol) was added. The mixture was stirred for 2 hours, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system A to give the title compound 4c (1 g, yield: 63%).
[0442] MS m / z(ESI): 404.2 [M+1].
[0443] Step 2
[0444] (±)-9-bromo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-d]pyridino[2,3-b][1,4]oxazaheptan-3-carboxylic acid tert-butyl ester 4d
[0445] Compound 4c (40 mg, 98.9 μmol) was dissolved in N,N-dimethylacetamide (2 mL), and N,N-diisopropylethylamine (38 mg, 294 μmol) was added. The mixture was reacted in a microwave oven at 140 °C for 2 hours. After cooling, the reaction solution was concentrated under reduced pressure to obtain the crude product, title compound 4d (38 mg, yield: 99%), which could be used for the next reaction without purification. MS m / z (ESI): 384.2 [M+1].
[0446] Step 3
[0447] (±)-3-(tert-butyl)9-methyl1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-d]pyridino[2,3-b][1,4]oxazaheptan-3,9-dicarboxylic acid ester 4e
[0448] The crude compound 4d (100 mg, 247.3 μmol) was dissolved in a mixed solvent of N,N-dimethylacetamide (2 mL) and methanol (5 mL), and palladium acetate (17 mg, 75.72 μmol), triethylamine (125 mg, 1.23 mmol), and 1,3-bis(diphenylphosphine)propane (30 mg, 72.72 μmol) were added. The reaction was carried out at 80 °C for 14 hours under a carbon monoxide atmosphere. After cooling, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system A to give the title compound 4e (40 mg, yield: 42.1%).
[0449] MS m / z(ESI): 364.2 [M+1].
[0450] The synthetic route in Example 1 was then used, and the starting material 1f in step 5 was replaced with compound 4e to obtain title compound 4 (130 mg, yield: 52.1%).
[0451] MS m / z(ESI):449.2[M+1].
[0452] 1H NMR (500MHz, CDCl3): δ11.38(s,1H),8.57(d,1H),7.90(q,1H),7.70(d,1H),7.6 8(d,1H),7.68-7.62(m,1H),7.19(d,1H),4.46(ddd,1H),4.28(ddd,1H),3.73(s, 2H),3.68(dd,1H),3.68-3.52(m,2H),3.02(d,3H),2.89-2.82(m,1H),2.78(qd,2 H),2.68(ddd,1H),2.57(ddd,1H),2.34(dd,1H),2.21-2.00(m,2H),1.35(t,3H).
[0453] Example 5
[0454] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-5-oxo-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-8-carboxamide 5
[0455]
[0456]
[0457] first step
[0458] (±)-8-bromo-5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-3-carboxylic acid benzyl ester 5b
[0459] Compound (±)-5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-3-carboxylic acid benzyl ester 5a (566 mg, 1.67 mmol, prepared by the method disclosed in Example 7 on page 6 of patent application “US4138564A”) was dissolved in dichloromethane (20 mL), and N-bromosuccinimide (297.7 mg, 1.67 mmol) was added in portions under ice bath. After the addition was complete, the reaction was maintained at the temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to give title compound 5b (343 mg, yield 35.8%).
[0460] MS m / z(ESI):417.2[M+1].
[0461] Step 2
[0462] (±)-3-benzyl8-methyl5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazine-3,8-dicarboxylic acid ester 5c
[0463] Compound 5b (335.00 mg, 802.86 μmol) was dissolved in methanol (5 mL) and N,N-dimethylformamide (5 mL), and then [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (327.55 mg, 401.40 μmol) and triethylamine (812.41 mg, 8.02 mmol) were added. The mixture was purged with carbon monoxide three times, stirred at 70 °C for 14 hours, cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to give title compound 5c (20 mg, yield: 6.2%).
[0464] MS m / z(ESI): 397.2 [M+1].
[0465] Step 3
[0466] (±)-8-(methylaminocarbonyl)-5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazine-3-carboxylic acid benzyl ester 5d
[0467] The crude product compound 5c (20 mg, 48.7 μmol) was dissolved in ethanol (5 mL), and 5 mL of 1 M methylamine ethanol solution was added. The mixture was stirred and reacted for 14 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound 5d (18 mg, yield: 93.4%). The product was directly used for the next reaction without purification.
[0468] MS m / z(ESI): 396.2 [M+1].
[0469] Step 4
[0470] (±)-N-methyl-5-oxo-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]pyridino[2,3-e]pyrazino-8-carboxamide 5e
[0471] The crude compound 5d (20 mg, 50.58 μmol) was dissolved in 2 mL of 30% hydrobromic acid-acetic acid solution, and the mixture was stirred for 1.5 hours. The reaction solution was concentrated under reduced pressure to give the crude title compound 5e (10 mg, yield: 75%), which was then directly proceeded to the next step of the reaction without purification.
[0472] MS m / z(ESI):262.2[M+1].
[0473] Step 5
[0474] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-5-oxo-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-8-carboxamide 5
[0475] Compound 5e (11 mg, 42.1 μmol), compound 1i (10 mg, 44.9 μmol), N,N-diisopropylethylamine (29 mg, 224.3 μmol), and sodium iodide (2 mg, 13 μmol) were dissolved in acetonitrile (3 mL). The mixture was reacted at 80 °C for 5 hours. After the reaction solution was concentrated under reduced pressure, the crude product was purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to obtain title compound 5 (3 mg, yield: 14.9%).
[0476] MS m / z(ESI):448.2[M+1].
[0477] 1H NMR (500MHz, CD3OD): δ8.56(d,1H),7.84(s,1H),7.77(d,1H),7.71(d,1H),7.24(d,1H),5.34(t,2H),3.8 9-3.79(m,3H),2.93(s,1H),2.67(q,2H),2.41-2.26(m,2H),2.19(t,2H),1.64-1.57(m,2H),0.90(t,3H).
[0478] Example 6
[0479] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-8-carboxamide 6
[0480]
[0481] first step
[0482] (±)-3-benzyl-8-methyl 1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazine-3,8-dicarboxylic acid ester 6a
[0483] Compound 5c (7 mg, 17.65 μmol) was dissolved in tetrahydrofuran (1 mL), and 0.2 mL of 1 M borane tetrahydrofuran solution was added. The mixture was heated to 40 °C and reacted for 1 hour. After the reaction was completed, methanol was added and stirred for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by thin-layer chromatography using solvent system A to give the title compound 6a (4 mg, yield: 59.2%).
[0484] MS m / z(ESI): 383.2 [M+1].
[0485] The synthetic route in Example 5 was then used, with the starting compound 5c in the third step replaced by compound 6a, to obtain title compound 6 (1 mg, yield: 21.6%).
[0486] MS m / z(ESI):434.2[M+1].
[0487] 1H NMR (500MHz, CDCl3): δ9.38(s,1H),8.51(s,1H),7.85(s,1H),7.63(s,1H),7.54-7.45(m,2H),7.07(d,1H),6.86(d,1H),4.72(s, 1H),3.77-3.59(m,3H),3.44-3.33(m,2H),3.28-3.19(m,1H),3.07-2.87(m,4H),2.85-2.65(m,3H),2.25(td,2H),0.90(dt,3H).
[0488] Example 7
[0489] (±)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N,6-dimethyl-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-8-carboxamide 7
[0490]
[0491] first step
[0492] (±)-6-methyl-5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-3-carboxylic acid benzyl ester 7a
[0493] Compound 5a (1.50 g, 4.43 mmol) was dissolved in tetrahydrofuran (10 mL), and sodium hydride (265.96 mg, 6.64 mmol, 60% purity) was added under ice bath conditions. After stirring at room temperature for 0.5 hours, methyl iodide (1.88 g, 13.24 mmol) was added under ice bath conditions, and the reaction was stirred for 5 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to give the title compound 7a (940 mg, yield: 60.2%).
[0494] MS m / z(ESI): 353.2 [M+1].
[0495] Step 2
[0496] (±)-8-bromo-6-methyl-5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazin-3-carboxylic acid benzyl ester 7b
[0497] Compound 7a (620 mg, 1.75 mmol) was dissolved in dichloromethane (10 mL), and N-bromosuccinimide (313.15 mg, 1.75 mmol) was added in portions under ice bath conditions. After the addition was complete, the reaction mixture was kept at the same temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system B to give the title compound 7b (660 mg, yield: 86.9%).
[0498] MS m / z(ESI):431.2[M+1].
[0499] Step 3
[0500] (±)-3-benzyl8-methyl-6-methyl-5-oxo-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazine-3,8-dicarboxylic acid ester 7c
[0501] Compound 7b (220 mg, 510.1 μmol) was dissolved in methanol (5 mL) and N,N-dimethylformamide (5 mL), followed by the addition of [1,1'-bis(diphenylphosphine)ferrocene]palladium dichloride dichloromethane complex (208.1 mg, 255 μmol) and triethylamine (516.1 mg, 5.1 mmol). The mixture was purged three times with carbon monoxide and stirred at 70 °C for 14 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system B to give the title compound 7c (180 mg, yield: 86.1%).
[0502] MS m / z(ESI):411.2[M+1].
[0503] Step 4
[0504] (±)-3-benzyl8-methyl-6-methyl-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]pyridino[2,3-e]pyrazine-3,8-dicarboxylic acid ester 7d
[0505] Compound 7c (80 mg, 194.92 μmol) was dissolved in tetrahydrofuran (4 mL), and 2 mL of 1 M boranetetrahydrofuran solution was added. The mixture was heated to 50 °C and reacted for 1 hour. After the reaction was completed, methanol was added and stirred for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system B to give the title compound 7d (61 mg, yield: 78.9%).
[0506] MS m / z(ESI): 397.2 [M+1].
[0507] The synthetic route in Example 5 was then used, with the starting compound 5c in the third step replaced by compound 7d, to obtain title compound 7 (5.4 mg, yield: 8%).
[0508] MS m / z(ESI):448.2[M+1].
[0509] 1H NMR (500MHz, CDCl3): δ10.58(s,1H),8.52(s,1H),7.87(s,1H),7.73(d,1H),7.66(s,1H),7.48(d,1H),6.78(d,1H),3.80-3.65(m,2H),3.6 2(d,1H),3.40-3.22(m,3H),3.10(s,3H),3.03(d,3H),2.96-2.82(m, 2H),2.74(q,2H),2.40(t,1H),2.09-1.90(d,2H),1.37-1.31(m,3H).
[0510] Example 8
[0511] (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-9-carboxamide 8
[0512]
[0513] first step
[0514] (R)-3-(((6-bromo-3-fluoropyridin-2-yl)methoxy)methyl)piperazine-1-carboxylic acid tert-butyl ester 8b
[0515] Compound 3b (2.5 g, 9.29 mmol) and compound (R)-3-(hydroxymethyl)piperazine-1-carboxylic acid tert-butyl ester 8a (2.25 g, 10.40 mmol, Shanghai Hanhong) were dissolved in tetrahydrofuran (30 mL). Sodium hydride (812.5 mg, 21.20 mmol, 60% purity) was added under ice bath conditions, and the mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system A to give the title compound 8b (3 g, yield: 79.8%).
[0516] MS m / z(ESI):404.1[M+1].
[0517] Step 2
[0518] (R)-3-(((6-(ethoxycarbonyl)-3-fluoropyridin-2-yl)methoxy)methyl)piperazine-1-carboxylic acid tert-butyl ester 8c
[0519] Compound 8b (2 g, 4.94 mmol) was dissolved in a mixed solvent of N,N-dimethylformamide (20 mL) and ethanol (10 mL), and bis(triphenylphosphine)palladium dichloride (0.52 g, 740.8 μmol) and N,N-diisopropylethylamine (1.52 g, 15 mmol) were added. The mixture was stirred at 100 °C for 14 hours under a carbon monoxide atmosphere. After cooling, the mixture was diluted with ethyl acetate (100 mL), washed successively with water and saturated sodium chloride solution, and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate, filtered to remove the desiccant, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system B to give the title compound 8c (1.5 g, yield: 76.2%).
[0520] MS m / z(ESI): 398.2 [M+1].
[0521] Step 3
[0522] 3-(tert-butyl)9-ethyl(R)-1,2,4a,5-tetrahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-3,9(4H)-dicarboxylic acid ester 8d
[0523] Compound 8c (4 g, 10.06 mmol) was dissolved in N,N-dimethylacetamide (20 mL), and N,N-diisopropylethylamine (4 g, 30.9 mmol) was added. The mixture was reacted in a microwave oven at 140 °C for 6 hours. After cooling, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system A to give the title compound 8d (2.3 g, yield: 60%). MS m / z (ESI): 378.2 [M+1].
[0524] Step 4
[0525] (R)-9-(methylaminocarbonyl)-1,2,4a,5-tetrahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-3(4H)-tert-butyl carboxylate 8e
[0526] Compound 8d (600 mg, 1.58 mmol) was dissolved in 5 mL of 1 M methylamine in ethanol, and the mixture was stirred for 14 hours. The reaction solution was concentrated under reduced pressure to obtain crude title compound 8e (570 mg, yield: 98%). The product was used directly in the next reaction without purification.
[0527] MS m / z(ESI): 363.2 [M+1].
[0528] Step 5
[0529] (R)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-9-carboxamide hydrochloride 8f
[0530] The crude compound 8e (140 mg, 386.2 μmol) was dissolved in dichloromethane (3 mL), and 1 mL of 4 M dioxane hydrochloride solution was added. The mixture was stirred for 2 hours. The reaction solution was concentrated under reduced pressure to obtain the crude title compound 8f (110 mg, yield: 95%). The product was used directly in the next step of the reaction without purification.
[0531] MS m / z(ESI):263.2[M+1].
[0532] Step 6
[0533] (R)-3-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthid-3-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-9-carboxamide 8
[0534] The crude compound 8f (570 mg, 1.9 mol), compound 1i (430 mg, 1.93 mol), and N,N-diisopropylethylamine (1.5 g, 11.6 mmol) were dissolved in acetonitrile (30 mL), and sodium iodide (30 mg, 200 μmol) were added. The mixture was reacted at 80 °C for 5 hours. After the reaction solution was concentrated under reduced pressure, the crude product was purified by high performance liquid chromatography (Waters-2545, column: SharpSil-T C18, 30*150 mm, 5 μm; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 30%-45%, flow rate: 30 mL / min) to obtain the title compound 8 (5.4 mg, yield: 8%).
[0535] MS m / z(ESI):449.2[M+1].
[0536] 1H NMR (500MHz, CD3OD): δ8.51(d,1H),7.93(d,1H),7.86(s,1H),7.79(d,1H),7.50(d,1H),4.99(t,2H),4.85(d,1H),4.08(dd,2H) ,3.87(dd,1H),3.81-3.71(m,2H),3.46(ddd,2H),2.95(s,3H),2.86-2.78(m,1H),2.75-2.61(m,3H),2.57(dd,1H),1.31(t,3H).
[0537] Example 9
[0538] (R)-3-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-9-carboxamide
[0539]
[0540] first step
[0541] 7-(chloromethyl)-8-fluoro-3-methylquinoxalin-2(1H)-one 9b
[0542] Compound 9a (100 mg, 480 μmol, prepared by the method disclosed in Intermediate 17 on page 35 of patent application "WO2021260093A1") was dissolved in dichloromethane (4 mL), phosphorus oxychloride (3 mL) was added, and the mixture was stirred for 14 hours. After the reaction solution was concentrated under reduced pressure, ice water was added, and a solid precipitated out. The solid was filtered, and the filter cake was washed with water and dried to obtain the crude title compound 9b (90 mg). The product was used directly in the next reaction without purification. MS m / z (ESI): 227.2 [M+1].
[0543] Step 2
[0544] (R)-3-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydro-7H-pyrazino[2,1-c]pyridino[3,2-e][1,4]oxazaheptan-9-carboxamide
[0545] The crude compound 9b (136 mg, 601 μmol), compound 8f (255 mg, 601 μmol), N,N-diisopropylethylamine (233 mg, 1.8 mmol), and sodium iodide (18 mg, 125.6 μmol) were dissolved in acetonitrile (3 mL) and reacted at 80 °C for 3 hours. After the reaction solution was concentrated under reduced pressure, the crude product was purified by high performance liquid chromatography (Waters-2545, column: YMC Triart-Exrs, Prep 30*150 mm, 5 μm, C18; mobile phase: aqueous phase (10 mmol / L ammonium bicarbonate) and acetonitrile, gradient ratio: acetonitrile 35%-45%, flow rate: 30 mL / min) to obtain the title compound 9 (40 mg, yield: 14.6%).
[0546] MS m / z(ESI):453.2[M+1].
[0547] 1 H NMR (500MHz, CD3OD): δ7.93(d,1H),7.57(d,1H),7.48(d,1H),7.40(t,1H),4.97(d,1H),4.91(s,1H),4.01(dd,1H ),3.85(dd,1H),3.80(s,2H),3.41(td,3H),2.95(s,3H),2.83(dq,1H),2.73(dd,1H),2.60(ddd,2H),2.53(s,3H).
[0548] Example 10
[0549] (R)-3-((5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)-N-methyl-1,2,3,4,4a,5-hexahydropyrazino[1,2-d]pyrido[2,3-b][1,4]oxazine-8-carboxamide 10
[0550]
[0551] Using the synthetic route in Example 2, the starting compound 1i in step 6 was replaced with compound 9b to obtain title compound 10 (84 mg, yield: 30.5%).
[0552] MS m / z(ESI):439.2[M+1].
[0553] 1 H NMR (500MHz, CD3OD): δ7.63(d,1H),7.57(d,1H),7.41(t,1H),7.25(d,1H),4.42(dd,1H),4.1 3(t,1H),3.80(d,3H),3.29(s,3H),3.08(d,1H),3.00(d,1H),2.94-2.85(m,4H),2.53(s,3H).
[0554] Biological evaluation
[0555] The following test examples further describe and explain this disclosure, but these test examples are not intended to limit the scope of this disclosure.
[0556] Test Example 1: Cell Proliferation Experiment
[0557] The following method detects intracellular ATP levels and, based on IC50... 50 Size evaluation of the disclosed compounds on DLD1 cells, DLD1 BRCA2- / - The inhibitory effect on the proliferation of MDA-MB-436 cells was investigated. The experimental methods are briefly described below:
[0558] I. Experimental Materials and Instruments
[0559] 1. DLD1, human colon cancer tumor cells (Nanjing Kebai, CBP60037)
[0560] 2.DLD1 BRCA2- / - Human BRCA2 gene knockout colon cancer cells (Creative biogene, CSC-RT0015)
[0561] 3. MDA-MB-436, human breast cancer cells (ATCC, HTB-130)
[0562] 4. Fetal bovine serum (GIBCO, 10091-148)
[0563] 5. CellTite-Glo reagent (Promega, G7573)
[0564] 6. 96-well cell culture plate (corning, 3903)
[0565] 7. Pancreatic enzyme (invitrogen, 25200-072)
[0566] 8. Microplate reader (BMG, Pherasta)
[0567] 9. Cell counter (Shanghai Ruiyu Biotechnology Co., Ltd., IC1000)
[0568] II. Experimental Procedure
[0569] DLD1 cells were cultured in RPMI-1640 medium containing 10% FBS, passaged 2-3 times per week at a passage ratio of 1:6 or 1:8. During passage, cells were digested with trypsin and transferred to centrifuge tubes, centrifuged at 1200 rpm for 3 minutes, the supernatant was discarded, and the cells were resuspended in fresh medium. 180 μL of the cell suspension was added to each 96-well cell culture plate, at a density of 2.78 × 10⁻⁶ cells / well. 3 Cells / mL, add only 180 μL of complete culture medium to the periphery of the 96-well plate.
[0570] DLD1 BRCA2- / - Cells were cultured in RPMI-1640 medium containing 10% FBS, passaged 2-3 times per week at a passage ratio of 1:6 or 1:8. During passage, cells were digested with trypsin and transferred to centrifuge tubes, centrifuged at 1200 rpm for 3 minutes, the supernatant was discarded, and the cells were resuspended in fresh medium. 180 μL of the cell suspension was added to each 96-well cell culture plate, resulting in a density of 8.34 × 10⁻⁶ cells / well. 3Cells / mL, add only 180 μL of complete culture medium to the periphery of the 96-well plate.
[0571] MDA-MB-436 cells were cultured in Leibovitz's L-15 medium containing 10% FBS, 10 μg / mL insulin, and 16 μg / mL glutathione, and passaged 2–3 times per week at a passage ratio of 1:3 or 1:5. During passage, cells were digested with trypsin and transferred to centrifuge tubes, centrifuged at 1200 rpm for 3 minutes, and the supernatant was discarded. The cells were resuspended in fresh medium. 180 μL of the cell suspension was added to each 96-well cell culture plate, resulting in a density of 8.34 × 10⁻⁶ cells / well. 3 Cells / mL, add only 180 μL of complete culture medium to the periphery of the 96-well plate.
[0572] The culture plates were incubated in an incubator for 24 hours (37°C, 5% CO2).
[0573] The test samples were diluted to 2 mM with DMSO, and then serially diluted 3-fold to obtain 10 concentrations, with blank and control wells provided. 5 μL of the prepared gradient concentration test compound solutions were added to 95 μL of fresh culture medium. Then, 20 μL of the above drug-containing culture medium solution was added to the culture plate. The culture plate was incubated for 6 days (37℃, 5% CO2). In a 96-well cell culture plate, 90 μL of CellTiter-Glo reagent was added to each well, and the plate was incubated at room temperature in the dark for 5–10 min. The chemiluminescence signal values were read using Pherastar, and the data were processed using GraphPad software. The results are shown in Table 1.
[0574] Table 1. The effects of the disclosed compounds on DLD1 and DLD1 BRCA2- / - Inhibitory effect on the proliferation of MDA-MB-436 cells
[0575]
[0576] Conclusion: The disclosed compound is effective against DLD1. BRCA2- / - It has a good inhibitory effect on the proliferation of MDA-MB-436 cells.
[0577] Test Example 2: Determination of the binding activity of the disclosed compounds on PARP1 and PARP2.
[0578] The in vitro PARP1 and PARP2 binding activity was tested using the following methods.
[0579] I. Experimental Materials and Instruments
[0580] 1. PARP1 recombinant protein (Sino Biotech, catalog number 11040-H08B);
[0581] 2. Recombinant PARP2 protein (BPS, catalog number 80502)
[0582] 3. Fluorescent probe (made in-house using a compound with CAS number 1380359-84-1, Shanghai Hengrui);
[0583] 4. 384-well plate (Corning, 3575)
[0584] 5. Pherastar FS microplate reader (BMG Labtech)
[0585] II. Experimental Procedure
[0586] Add 8 μL of binding buffer to each well of a 384-well plate; dissolve the fluorescent probe in dimethyl sulfoxide (DMSO) and dilute to the appropriate concentration. Then, dilute the DMSO-prepared fluorescent probe 20-fold in binding buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM MgCl2, 0.1 mM EDTA, 0.01% IGEPA), adding 2 μL to each well; dissolve the test compound in DMSO and dilute to various concentration gradients as needed. Then, dilute each concentration of the compound prepared in DMSO 20-fold in binding buffer, adding 2 μL to each well; dilute PARP1 or PARP2 protein to the appropriate concentration using binding buffer, adding 8 μL / well to a black 384-well plate, mixing thoroughly, and incubating at 25°C for 40 minutes. Read the signal values using the FP program in the Pherastar FS microplate reader. Data were processed using GraphPad software.
[0587] The PARP1 and PARP2 binding inhibitory activities of the disclosed compounds were determined by the above experiments, and the measured IC50 values were... 50 The values are shown in Table 2.
[0588] Table 2 shows the inhibitory activity of the compounds disclosed in this study on PARP1 and PARP2 binding.
[0589]
[0590] Conclusion: The compound disclosed herein exhibits selective inhibition of PARP1.
Claims
1. A compound of general formula (IM) or a pharmaceutically acceptable salt thereof: in: X is (CR 4a R 4b ) m or C(O); Y is selected from NR 5 (CR 4c R 4d ) r and O(CR 4e R 4f ) n ; R 4a , R 4b , R 4c , R 4d , R 4e and R 4f are selected from a hydrogen atom; R 5 selected from a hydrogen atom, C 1-6 alkyl group; G 1 and G 2 are the same or different and each independently CR 6 or a nitrogen atom; G 3 for CR 6 ; R 0 R 1 and R 6 They may be the same or different, and each is independently selected from hydrogen atoms, halogens, and carbon atoms. 1-6 alkyl; Each R 2 They may be the same or different, and each is independently selected from halogens, C 1-6 alkyl; Each R 3 Selected from -C(O)NR 7a R 7b ; R 7a R 7b Whether the atoms are the same or different, and each is independently selected from hydrogen atoms, C atoms 1-6 alkyl; m is 0, 1, or 2; n is 0 or 1; r is 0; s is 0; and t is 1; The condition is not 。 2. The compound of formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, is a compound of formula (I) or a pharmaceutically acceptable salt thereof. in, G 1 To G 3 R 1 To R 3 X, Y, s, and t are as defined in claim 1; The condition is not: 。 3. The compound of general formula (IM) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein XY is selected from CH2O, CH2OCH 2、 CH2CH2O, C(O)NH, CH2NH or CH2NCH3.
4. The compound of general formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound is of general formula (II-1) or a pharmaceutically acceptable salt thereof: in: X is (CR) 4a R 4b ) m ; G 1 To G 3 R 1 To R 3 R 4a R 4b , s, t, m and n are as defined in claim 1 or 2.
5. The compound of formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2.
6. The compound of general formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein G 1 For CH, G 2 For nitrogen atoms; or G 1 For nitrogen atoms, G 2 For CH.
7. The compound of general formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the compound is of general formula (III-1) or general formula (III-1-A) or a pharmaceutically acceptable salt thereof: or in: m1 is 0 or 1; R 1 R 6 R 7a R 7b and n as defined in claim 1 or 2.
8. The compound of general formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from C 1-6 alkyl.
9. The compound of general formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 1 Selected from ethyl.
10. The compound of general formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 6 Selected from hydrogen atoms.
11. The compound of formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 7a Selected from hydrogen atoms, R 7b Selected from methyl.
12. The compound of formula (IM) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, selected from any of the following compounds: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 。 13. A compound of general formula (IMa) or a salt thereof: in: t is 1, 2, or 3; X, Y, R 2 R 3 and s as defined in claim 1, The condition is not .
14. A compound of general formula (II-1a) or a salt thereof, X, R 2 R 3 , t, n and s are as defined in claim 1 or 2.
15. A compound or a salt thereof, selected from: , , , , , , , , , , , , , , , , , , , , , , , , , , , , and .
16. A method for preparing a compound of formula (IM) according to claim 1 or a pharmaceutically acceptable salt thereof, the method comprising: A compound of general formula (IMa) or a salt thereof undergoes a nucleophilic substitution reaction with a compound of general formula (IMb) to give a compound of general formula (IM) or a pharmaceutically usable salt thereof. in: L represents a halogen; X, Y, G 1 To G 3 R 0 To R 3 , s and t are as defined in claim 1.
17. A method for preparing a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt thereof, the method comprising: A compound of general formula (IMa) or a salt thereof undergoes a nucleophilic substitution reaction with a compound of general formula (V) to give a compound of general formula (I) or a pharmaceutically usable salt thereof; in: L represents a halogen; X, Y, G 1 To G 3 R 0 To R 3 , s and t are as defined in claim 2.
18. The method of claim 16 or 17, wherein the salt of the compound of the general formula (IMa) is a hydrochloride salt.
19. The method of claim 16 or 17, wherein the L is a chlorine atom.
20. A pharmaceutical composition comprising a compound of formula (IM) according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
21. Use of the compound of general formula (IM) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 20, in the preparation of a medicament for treating and / or preventing cancer; wherein the cancer is selected from cervical cancer, endometrial cancer, bile duct cancer, bladder cancer, testicular cancer, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, colorectal cancer, and lung cancer.
Citation Information
Patent Citations
Tetrahydro{8 1H{9 pyrazino{8 1,2-a{9 azaquinoxalin-5(6H)-ones and derivatives thereof
US4138564A
Quinolinone derivatives as PARP and tank inhibitors
WO2008107478A1
Quinolinone derivatives as PARP inhibitors
WO2009053373A1
Aurora a kinase inhibitor
WO2016077161A1
Quinoxaline derivatives as Anti-cancer drugs
WO2021260092A1
